Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus

Physiology and Behavior

Volumn 166, Issue , 2016, Pages 14-21

  Felger, Jennifer C ^a,b   Haroon, Ebrahim ^a,b   Woolwine, Bobbi J ^a   Raison, Charles L ^c,d   Miller, Andrew H ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Depression; Dexamethasone; Fatigue; Hepatitis C virus; HPA axis; Inflammation

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; ALPHA INTERFERON; ANTIVIRUS AGENT; CORTICOTROPIN;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; MALE; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; AREA UNDER THE CURVE; BLOOD; CHEMICALLY INDUCED; COMPLICATION; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RADIOIMMUNOASSAY;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DEXAMETHASONE; FATIGUE; FEMALE; GLUCOCORTICOIDS; HEPATITIS C; HUMANS; HYDROCORTISONE; INFLAMMATION; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RADIOIMMUNOASSAY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84950277855     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.12.013     Document Type: Article

References (65)

1. [1] Abercrombie, H.C., Giese-Davis, J., Sephton, S., Epel, E.S., Turner-Cobb, J.M., Spiegel, D., Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 29 (2004), 1082–1092.
2. [2] Asnis, G.M., De La Garza, R. II, Miller, A.H., Raison, C.L., Ribavirin may be an important factor in IFN-induced neuropsychiatric effects. J. Clin. Psychiatry, 65, 2004, 581 (author reply 581-582).
3. [3] Bower, J.E., Ganz, P.A., Aziz, N., Fahey, J.L., Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64 (2002), 604–611.
4. [4] Bower, J.E., Ganz, P.A., Dickerson, S.S., Petersen, L., Aziz, N., Fahey, J.L., Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30 (2005), 92–100.
5. [5] Bower, J.E., Ganz, P.A., Irwin, M.R., Arevalo, J.M., Cole, S.W., Fatigue and gene expression in human leukocytes: increased NF-kappaB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 25 (2011), 147–150.
6. [6] Capuron, L., Pagnoni, G., Demetrashvili, M.F., Lawson, D.H., Fornwalt, F.B., Woolwine, B., Berns, G.S., Nemeroff, C.B., Miller, A.H., Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 32, 2007, 2384–2392.
7. [7] Champaneri, S., Xu, X., Carnethon, M.R., Bertoni, A.G., Seeman, T., DeSantis, A.S., Diez Roux, A., Shrager, S., Golden, S.H., Diurnal salivary cortisol is associated with body mass index and waist circumference: the Multiethnic Study of Atherosclerosis. Obesity 21 (2013), E56–E63.
8. [8] Cole, S.W., Hawkley, L.C., Arevalo, J.M., Sung, C.Y., Rose, R.M., Cacioppo, J.T., Social regulation of gene expression in human leukocytes. Genome Biol., 8, 2007, R189.
9. [9] Dallman, M.F., Akana, S.F., Pecoraro, N.C., Warne, J.P., la Fleur, S.E., Foster, M.T., Glucocorticoids, the etiology of obesity and the metabolic syndrome. Curr. Alzheimer Res. 4 (2007), 199–204.
10. [10] Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctot, K.L., A meta-analysis of cytokines in major depression. Biol. Psychiatry 67 (2010), 446–457.
11. [11] Engler, H., Bailey, M.T., Engler, A., Stiner-Jones, L.M., Quan, N., Sheridan, J.F., Interleukin-1 receptor type 1-deficient mice fail to develop social stress-associated glucocorticoid resistance in the spleen. Psychoneuroendocrinology 33 (2008), 108–117.
12. [12] Evans, D.L., Charney, D.S., Lewis, L., Golden, R.N., Gorman, J.M., Krishnan, K.R., Nemeroff, C.B., Bremner, J.D., Carney, R.M., Coyne, J.C., Delong, M.R., Frasure-Smith, N., Glassman, A.H., Gold, P.W., Grant, I., Gwyther, L., Ironson, G., Johnson, R.L., Kanner, A.M., Katon, W.J., Kaufmann, P.G., Keefe, F.J., Ketter, T., Laughren, T.P., Leserman, J., Lyketsos, C.G., McDonald, W.M., McEwen, B.S., Miller, A.H., Musselman, D.L., O'Connor, C., Petitto, J.M., Pollock, B.G., Robinson, R.G., Roose, S.P., Rowland, J., Sheline, Y., Sheps, D.S., Simon, G., Spiegel, D., Stunkard, A., Sunderland, T., Tibbits, P.J., Valvo, W.J., Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 58 (2005), 175–189.
13. [13] Felger, J.C., Alagbe, O., Pace, T.W., Woolwine, B.J., Hu, F., Raison, C.L., Miller, A.H., Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav. Immun. 25 (2011), 1094–1098.
14. [14] Felger, J.C., Cole, S.W., Pace, T.W., Hu, F., Woolwine, B.J., Doho, G.H., Raison, C.L., Miller, A.H., Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol. Med. 42 (2012), 1591–1603.
15. [15] Felger, J.C., Cole, S.W., Pace, T.W., Hu, F., Woolwine, B.J., Doho, G.H., Raison, C.L., Miller, A.H., Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol. Med., 2015, 1–13 (in press).
16. [16] Felger, J.C., Li, L., Marvar, P.J., Woolwine, B.J., Harrison, D.G., Raison, C.L., Miller, A.H., Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav. Immun. 31 (2013), 153–160.
17. [17] Felger, J.C., Lotrich, F.E., Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246 (2013), 199–229.
18. [18] First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B., Structured Clinical Interview for DSM-IV. 1997, American Psychiatric Press, Washington DC.
19. [19] Giese-Davis, J., Sephton, S.E., Abercrombie, H.C., Duran, R.E., Spiegel, D., Repression and high anxiety are associated with aberrant diurnal cortisol rhythms in women with metastatic breast cancer. Health Psychol. 23 (2004), 645–650.
20. [20] Haroon, E., Raison, C.L., Miller, A.H., Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37 (2012), 137–162.
21. [21] Heim, C., Bradley, B., Mletzko, T.C., Deveau, T.C., Musselman, D.L., Nemeroff, C.B., Ressler, K.J., Binder, E.B., Effect of childhood trauma on adult depression and neuroendocrine function: sex-specific moderation by CRH receptor 1 gene. Front. Behav. Neurosci., 3, 2009, 41.
22. [22] Heim, C., Mletzko, T., Purselle, D., Musselman, D.L., Nemeroff, C.B., The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol. Psychiatry 63 (2008), 398–405.
23. [23] Howren, M.B., Lamkin, D.M., Suls, J., Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 71 (2009), 171–186.
24. [24] Hu, F., Pace, T.W., Miller, A.H., Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain Behav. Immun. 23 (2009), 455–463.
25. [25] Hubain, P.P., Staner, L., Dramaix, M., Kerkhofs, M., Papadimitriou, G., Mendlewicz, J., Linkowski, P., The dexamethasone suppression test and sleep electroencephalogram in nonbipolar major depressed inpatients: a multivariate analysis. Biol. Psychiatry 43 (1998), 220–229.
26. [26] Jarcho, M.R., Slavich, G.M., Tylova-Stein, H., Wolkowitz, O.M., Burke, H.M., Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol. Psychol. 93 (2013), 150–158.
27. [27] Judd, A.M., MacLeod, R.M., Differential release of tumor necrosis factor and IL-6 from adrenal zona glomerulosa cells in vitro. Am. J. Physiol. 268 (1995), E114–E120.
28. [28] Lopresti, A.L., Maes, M., Maker, G.L., Hood, S.D., Drummond, P.D., Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord. 167 (2014), 368–375.
29. [29] Matthews, K., Schwartz, J., Cohen, S., Seeman, T., Diurnal cortisol decline is related to coronary calcification: CARDIA study. Psychosom. Med. 68 (2006), 657–661.
30. [30] Miller, A.H., Haroon, E., Raison, C.L., Felger, J.C., Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress. Anxiety 30 (2013), 297–306.
31. [31] Miller, G.E., Chen, E., Sze, J., Marin, T., Arevalo, J.M., Doll, R., Ma, R., Cole, S.W., A functional genomic fingerprint of chronic stress in humans: blunted glucocorticoid and increased NF-kappaB signaling. Biol. Psychiatry 64 (2008), 266–272.
32. [32] Monk, J.P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L.J., Otterson, G.A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., Caligiuri, M.A., Villalona-Calero, M.A., Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 24 (2006), 1852–1859.
33. [33] Montgomery, S.A., Asberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979), 382–389.
34. [34] Musselman, D.L., Lawson, D.H., Gumnick, J.F., Manatunga, A.K., Penna, S., Goodkin, R.S., Greiner, K., Nemeroff, C.B., Miller, A.H., Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 344 (2001), 961–966.
35. [35] Musselman, D.L., Miller, A.H., Porter, M.R., Manatunga, A., Gao, F., Penna, S., Pearce, B.D., Landry, J., Glover, S., McDaniel, J.S., Nemeroff, C.B., Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am. J. Psychiatry 158 (2001), 1252–1257.
36. [36] Nikkheslat, N., Zunszain, P.A., Horowitz, M.A., Barbosa, I.G., Parker, J.A., Myint, A.M., Schwarz, M.J., Tylee, A.T., Carvalho, L.A., Pariante, C.M., Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression. Brain Behav. Immun. 48 (2015), 8–18.
37. [37] Pace, T.W., Hu, F., Miller, A.H., Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav. Immun. 21 (2007), 9–19.
38. [38] Pace, T.W., Hu, F., Miller, A.H., Activation of cAMP-protein kinase A abrogates STAT5-mediated inhibition of glucocorticoid receptor signaling by interferon-alpha. Brain Behav. Immun. 25 (2011), 1716–1724.
39. [39] Pariante, C.M., Miller, A.H., Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiatry 49 (2001), 391–404.
40. [40] Pariante, C.M., Pearce, B.D., Pisell, T.L., Sanchez, C.I., Po, C., Su, C., Miller, A.H., The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 140 (1999), 4359–4366.
41. [41] Potter, G.G., Kittinger, J.D., Wagner, H.R., Steffens, D.C., Krishnan, K.R., Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology 29 (2004), 2266–2271.
42. [42] Prather, A.A., Rabinovitz, M., Pollock, B.G., Lotrich, F.E., Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav. Immun. 23 (2009), 1109–1116.
43. [43] Raison, C.L., Borisov, A.S., Majer, M., Drake, D.F., Pagnoni, G., Woolwine, B.J., Vogt, G.J., Massung, B., Miller, A.H., Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 65 (2009), 296–303.
44. [44] Raison, C.L., Borisov, A.S., Woolwine, B.J., Massung, B., Vogt, G., Miller, A.H., Interferon-alpha effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry, 2008.
45. [45] Raison, C.L., Borisov, A.S., Woolwine, B.J., Massung, B., Vogt, G., Miller, A.H., Interferon-alpha effects on diurnal hypothalamic–pituitary–adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol. Psychiatry 15 (2010), 535–547.
46. [46] Raison, C.L., Capuron, L., Miller, A.H., Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27 (2006), 24–31.
47. [47] Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15 (2010), 393–403.
48. [48] Raison, C.L., Demetrashvili, M., Capuron, L., Miller, A.H., Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 19 (2005), 105–123.
49. [49] Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 70 (2013), 31–41.
50. [50] Raison, C.L., Rye, D.B., Woolwine, B.J., Vogt, G.J., Bautista, B.M., Spivey, J.R., Miller, A.H., Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 68 (2010), 942–949.
51. [51] Rosmond, R., Bjorntorp, P., The hypothalamic–pituitary–adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. J. Intern. Med. 247 (2000), 188–197.
52. [52] Schrepf, A., Thaker, P.H., Goodheart, M.J., Bender, D., Slavich, G.M., Dahmoush, L., Penedo, F., DeGeest, K., Mendez, L., Lubaroff, D.M., Cole, S.W., Sood, A.K., Lutgendorf, S.K., Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology 53 (2015), 256–267.
53. [53] Sephton, S.E., Sapolsky, R.M., Kraemer, H.C., Spiegel, D., Diurnal cortisol rhythm as a predictor of breast cancer survival.[see comment]. J. Natl. Cancer Inst. 92 (2000), 994–1000.
54. [54] Silverman, M.N., Pearce, B.D., Biron, C.A., Miller, A.H., Immune modulation of the hypothalamic–pituitary–adrenal (HPA) axis during viral infection. Viral Immunol. 18 (2005), 41–78.
55. [55] Slavich, G.M., Understanding inflammation, its regulation, and relevance for health: a top scientific and public priority. Brain Behav. Immun. 45 (2015), 13–14.
56. [56] Smets, E.M., Garssen, B., Bonke, B., De Haes, J.C., The multidimensional fatigue inventory (MFI) psychometric qualities of an instrument to assess fatigue. J. Psychosom. Res. 39 (1995), 315–325.
57. [57] Smoak, K.A., Cidlowski, J.A., Mechanisms of glucocorticoid receptor signaling during inflammation. Mech. Ageing Dev. 125 (2004), 697–706.
58. [58] Spiegel, D., Giese-Davis, J., Taylor, C.B., Kraemer, H., Stress sensitivity in metastatic breast cancer: analysis of hypothalamic–pituitary–adrenal axis function. Psychoneuroendocrinology 31 (2006), 1231–1244.
59. [59] Ticher, A., Haus, E., Ron, I.G., Sackett-Lundeen, L., Ashkenazi, I.E., The pattern of hormonal circadian time structure (acrophase) as an assessor of breast-cancer risk. Int. J. Cancer 65 (1996), 591–593.
60. [60] Tkachenko, I.V., Jaaskelainen, T., Jaaskelainen, J., Palvimo, J.J., Voutilainen, R., Interleukins 1alpha and 1beta as regulators of steroidogenesis in human NCI-H295R adrenocortical cells. Steroids 76 (2011), 1103–1115.
61. [61] Torres, M.A., Pace, T.W., Liu, T., Felger, J.C., Mister, D., Doho, G.H., Kohn, J.N., Barsevick, A.M., Long, Q., Miller, A.H., Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer 119 (2013), 1951–1959.
62. [62] Tyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., Cella, D., Krishnan, R., Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006), 29–35.
63. [63] Vegiopoulos, A., Herzig, S., Glucocorticoids, metabolism and metabolic diseases. Mol. Cell. Endocrinol. 275 (2007), 43–61.
64. [64] Wang, X., Wu, H., Miller, A.H., Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Mol. Psychiatry 9 (2004), 65–75.
65. [65] Zunszain, P.A., Hepgul, N., Pariante, C.M., Inflammation and depression. Curr. Top. Behav. Neurosci. 14 (2013), 135–151.